Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial)
- PMID: 29502105
- PMCID: PMC5866323
- DOI: 10.1161/JAHA.117.007570
Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial)
Abstract
Background: There is still uncertainty about the safety of aprotinin for coronary artery bypass graft surgery. The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral versus single internal thoracic artery grafting. Many of the ART patients (≈30%) received perioperative aprotinin. We investigated the association between perioperative aprotinin administration and short-term (in-hospital) and long-term outcomes by performing a post hoc analysis of the ART.
Methods and results: Among patients enrolled in the ART (n=3102) from 2004 to 2007, we excluded those who did not undergo surgery (n=18) and those with no information about use of perioperative aprotinin (n=9). Finally, 836 of 3076 patients (27%) received aprotinin. Propensity matching was used to select 536 pairs for final comparison. Aprotinin was also associated with an increased risk of hospital mortality (9 [1.7%] versus 1 [0.2%]; odds ratio, 9.12; 95% confidence interval [CI], 1.15-72.2; P=0.03), intra-aortic balloon pump insertion (37 [6.9%] versus 17 [3.2%]; odds ratio, 2.26; 95% CI, 1.26-4.07; P=0.006), and acute kidney injury (102 [19.0%] versus 76 [14.2%]; odds ratio, 1.42; 95% CI, 1.03-1.97; P=0.03). Aprotinin was not associated with a lower incidence of transfusion (37 [6.9%] versus 28 [5.2%]; odds ratio, 1.34; 95% CI, 0.81-2.23; P=0.25) and reexploration (26 [4.9%] versus 19 [3.5%]; hazard ratio, 1.39; 95% CI, 0.76-2.53; P=0.28). At 5 years, all-cause mortality was significantly increased in the aprotinin group (56 [10.6%] versus 38 [7.3%]; hazard ratio, 1.51; 95% CI, 1.0-2.28; P=0.045).
Conclusions: In the present post hoc ART analysis, aprotinin was associated with a significantly increased risk of early and late mortality.
Clinical trial registration: URL: http://www.isrctn.com. Unique identifier: ISRCTN46552265.
Keywords: Surgery; aprotinin; coronary artery bypass graft surgery; outcomes; propensity score matching.
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Figures



References
-
- Kuduvalli M, Oo AY, Newall N, Grayson AD, Jackson M, Desmond MJ, Fabri BM, Rashid A. Effect of peri‐operative red blood cell transfusion on 30‐day and 1‐year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg. 2005;27:592–598. - PubMed
-
- Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation . The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353–365. - PubMed
-
- Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary artery bypass grafting and risk of death. N Engl J Med. 2008;358:771–783. - PubMed
-
- Shaw AD, Stafford‐Smith M, White WD, Phillips‐Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF. The effect of aprotinin on outcome after coronary‐artery bypass grafting. N Engl J Med. 2008;358:784–793. - PubMed
-
- Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A comparison of aprotinin and lysine analogues in high‐risk cardiac surgery. N Engl J Med. 2008;358:2319–2331. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical